Stock Events

Lilly(Eli) & 

€842.6
4637
+€10.2+1.23% Friday 15:53

Statistics

Day High
845.4
Day Low
828.1
52W High
-
52W Low
-
Volume
354
Avg. Volume
-
Mkt Cap
860.48B
P/E Ratio
140.18
Dividend Yield
0.57%
Dividend
4.8

Upcoming

Dividends

0.57%Dividend Yield
10Y Growth
10.25%
5Y Growth
15.05%
3Y Growth
15.21%
1Y Growth
15.04%

Earnings

8AugConfirmed
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
-0.2
0.79
1.78
2.76
Expected EPS
2.762838
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LLY.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

902.85Average Price Target
The highest estimate is €1,023.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

About

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Show more...
CEO
Mr. David A. Ricks
Employees
43000
Country
US
ISIN
US5324571083
WKN
000858560

Listings